Pfizer Turns To Lipitor DTC To Pump Up Lipid-Lowering Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer hopes new branded and unbranded ads will reinvigorate the cholesterol-lowering category following flat third-quarter sales for the statin in the U.S.
You may also be interested in...
Generic Competition May Have Taken A Bite Out Of Lipitor
The statin’s sales got off to a sluggish start in the first quarter but Pfizer maintains the drug will reach its $13 bil. revenue target for the year.
Generic Competition May Have Taken A Bite Out Of Lipitor
The statin’s sales got off to a sluggish start in the first quarter but Pfizer maintains the drug will reach its $13 bil. revenue target for the year.
Merck To Support Zocor Into 2006 Based On Strong Formulary Position
Position of Zocor, Vytorin on Express Scripts' preferred formulary is a win-win for Merck, CEO Clark states during Q3 call.